Articles

Novel antiepileptic for Dravet syndrome

New extended release formulation and preclinical data set stage for Phase 1b Trial to start in mid-2017
Brought to you byDDNews Staff
| 2 min read

MIAMI BEACH, Fla.—Biscayne Pharmaceuticals Inc. in October reported that a new scientific publication shows its lead compound BIS-001 can eliminate all seizures in the majority of animals in models of the type of epilepsy known as Dravet syndrome. BIS-001 is a clinical-stage, highly potent agent with a novel mechanism of action that is a synthetic form of huperzine A, an extract of a traditional Chinese medicine. Biscayne is initially developing BIS-001 for the treatment of children with Dravet syndrome and for adults with complex partial seizures.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.